HSK 39297
Alternative Names: HSK-39297Latest Information Update: 26 Dec 2024
Price :
$50 *
At a glance
- Originator Haisco Pharmaceutical Group
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II IgA nephropathy; Paroxysmal nocturnal haemoglobinuria
- Phase I Kidney disorders
Most Recent Events
- 20 Dec 2024 Phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria in China (PO) (NCT06745622)
- 12 Oct 2024 Phase-II clinical trials in IgA nephropathy in China (PO) (NCT06670352)
- 29 Sep 2024 Haisco Pharmaceutical completes a phase I trial (In volunteers) in China (PO) (NCT06350279)